HIGHLIGHTS
SUMMARY
Both local and systemic symptoms following 1 st and 2 nd dose (n=49 and 48, respectively) of SARS-CoV-2 mRNA_vaccines were predictive of higher AB after vaccination. Studies have also shown that vaccination with mRNA_vaccines results in rapid, robust antibody production and associated reactogenicity after the first vaccine dose as well as following heterologous booster doses. The authors investigated relationships between sociodemographic factors, reactogenicity, and immunogenicity following SARS-CoV-2 mRNA_vaccination among previously SARS-CoV-2 infected (COVID+) individuals participating in the longitudinal cohort study (COVID-19 ImmuniTY study, or "CITY"). Participants . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.